Research progress of neoadjuvant immunotherapy for non-small cell lung cancer and the challenge of evaluating therapeutic response with imaging methods

LIU Ying; ZHANG Yuwei; YE Zhaoxiang

doi:10.19732/j.cnki.2096-6210.2022.04.002

您当前的位置：

首页 >

文章列表页 >

Research progress of neoadjuvant immunotherapy for non-small cell lung cancer and the challenge of evaluating therapeutic response with imaging methods

更新时间：2025-12-15

- Research progress of neoadjuvant immunotherapy for non-small cell lung cancer and the challenge of evaluating therapeutic response with imaging methods
- Vol. 31, Issue 4, Pages: 350-356(2022)
- 作者机构：
  
  1. 天津市恶性肿瘤临床医学研究中心,天津,300060
  2. 天津医科大学肿瘤医院放射科，国家肿瘤临床医学研究中心,天津,300060
  3. 天津市&ldquo
  4. 肿瘤防治&rdquo
  5. 重点实验室,天津,300060
- 作者简介：
- 基金信息：
- DOI：10.19732/j.cnki.2096-6210.2022.04.002
  CLC：
- Published Online：28 August 2022，
  
  Published：28 August 2022
- 稿件说明：
移动端阅览
刘颖,张宇威,叶兆祥. 非小细胞肺癌新辅助免疫治疗进展及影像学疗效评价挑战[J]. 肿瘤影像学, 2022, 31(4): 350-356 https://doi.

org/10.19732/j.cnki.2096-6210.2022.04.002
刘颖,张宇威,叶兆祥. 非小细胞肺癌新辅助免疫治疗进展及影像学疗效评价挑战[J]. 肿瘤影像学, 2022, 31(4): 350-356 https://doi. DOI： 10.19732/j.cnki.2096-6210.2022.04.002.

org/10.19732/j.cnki.2096-6210.2022.04.002 DOI：

摘要

根治性手术切除是早期和部分局部晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的主要治疗方法，但术后远处和局部复发率较高，因此需要辅助系统性治疗，然而新辅助或辅助化疗仅能使这部分患者的总生存期（overall survival，OS）提高约5%。因此，对于早期可切除的NSCLC患者，迫切需要新的治疗方法。免疫检查点抑制剂的出现开启了肺癌治疗领域的新格局，可切除NSCLC新辅助免疫治疗临床试验如雨后春笋般涌现。本文针对新辅助免疫治疗在可切除NSCLC的初步研究结果和临床应用中存在的决策困惑特别是疗效评价和预测方面面临的挑战进行述评。

Abstract

Although surgical resection is the mainstay of treatment for patients with early stage and locally advanced stage of non-small cell lung cancer (NSCLC)

distant and local recurrence occur relatively frequently

justifying the need for systemic therapy. However

neoadjuvant or adjuvant chemotherapy leads to only a 5% improvement in overall survival (OS)

highlighting a critical need for therapeutic innovation for patients with resectable NSCLC. Immune checkpoint inhibitors have opened a new patternin the field of lung cancer treatment. Clinical trials of neoadjuvant immunotherapy for resectable NSCLC have sprung up. This review summarized early findings from reported and ongoing clinical trials that applied immunotherapy to neoadjuvant treatment for resectable NSCLC patients

and discussed the decision-making confusion of neoadjuvant immunotherapy in clinical application

especially the challenges faced by therapeutic efficacy evaluation and prediction.

关键词

Keywords

references

Views

1480

下载量

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application and research progress of PET/CT in evaluation of immunotherapy for non-small cell lung cancer

The predictive value of CT radiomics model for immunotherapy efficacy in non-small cell lung cancer

Research progress in predicting EGFR mutation of NSCLC patients using machine learning based on medical imaging

The treatment outcome and prognosis of CT-guided radiofrequency ablation for elderly patients with non-small cell lung cancer who cannot be treated with surgery

Prediction of distant metastasis in non-small cell lung cancer based on CT radiomics combined prediction model

Related Author

CHEN Yue

YANG Jian

LI Linwei

Wufei CHEN

Ying DONG

YE Xiaodan

SHEN Leilei

SUN Yuanxin

Related Institution

Department of Radiology, Huadong Hospital, Fudan University

Shanghai Institute of Medical Imaging

Department of Radiology, Zhongshan Hospital, Fudan University

Department of Internal Medicine 2, Nanning Red Cross Society Hospital

Transplant Medicine Center, The Second Affiliated Hospital of Guangxi Medical University

AI问答

⁰